The Top 5 Biosimilars Articles for the Week of February 10

Article

The Center for Biosimilars® recaps the top stories for the week of February 10, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 10, 2020.

Number 5: The European League Against Rheumatism (EULAR) updates guidelines to address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis.

Number 4: Patents on nearly 20 oncology biologics will expire by 2023, which could lead to more biosimilars in cancer care and lower costs, a review article says.

Number 3: At the Specialty Therapies and Biosimilars Congress, a review of the orphan drug market predicts hefty biosimilar competition, although patent struggles need resolution, according to one speaker.

Number 2: Also at the Congress, the director of pharmacy for Emory Healthcare discusses how they developed a strong in-house specialty pharmacy and cut dependence on outside for-profit specialty pharmacies and managed to strengthen adherence and improve patient outcomes.

Number 1: A review of the 2020 pipeline shows oncology biosimilars are starting to gain some traction in the marketplace.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of February 12, 2024.
Ha Kung Wong, JD
The top 5 biosimilar articles for the week of February 5, 2024.
The Top 5 Biosimilar Articles for the Week of January 29
Here are the top 5 biosimilar articles for the week of January 15, 2024.
The Top 5 Center for Biosimilars Articles for the Week of January 8, 2024.
Prerakkumar Parikh, PharmD
Here are the top 5 biosimilar articles for the week of January 1, 2024.
Related Content
© 2024 MJH Life Sciences

All rights reserved.